ImportanceAlthough β-blockers are a mainstay of treatment after acute myocardial infarction (AMI), these medications are commonly not prescribed for older nursing home residents after AMI, in part owing to concerns about potential functional harms and uncertainty of benefit.ObjectiveTo study the association of β-blockers after AMI with functional decline, mortality, and rehospitalization among long-stay nursing home residents 65 years or older.Design, setting, and participantsThis cohort study of nursing home residents with AMI from May 1, 2007, to March 31, 2010, used national data from the Minimum Data Set, version 2.0, and Medicare Parts A and D. Individuals with β-blocker use before AMI were excluded. Propensity score-based methods were...
Background: Long-term β-blockade therapy is beneficial in post-myocardial infarct (MI) patients with...
Aims: Guidelines concerning β-blocker treatment following acute myocardial infarction (AMI) are base...
BACKGROUND: Despite its proven efficacy, beta-blocker therapy remains underused in elderly patients ...
Objectives. —To study determinants and adverse outcomes (mortality and rehospitalization) of β-bloc...
Background Secondary prevention medications are often not prescribed to frail, older adults followin...
BackgroundEvidence regarding differences in outcomes between angiotensin II receptor blockers (ARBs)...
Background: We evaluated the burden of adverse events (AEs) caused by beta-blocker use after acute m...
ObjectivesStudies examining the effects of statins after acute myocardial infarction (AMI) excluded ...
Objectives: Studies examining the effects of statins after acute myocardial infarction (AMI) exclude...
Objectives: Studies examining the effects of statins after acute myocardial infarction (AMI) exclude...
Background/objectivesSecondary prevention medications are recommended for older adults after acute m...
AimsTo assess whether nursing home (NH) residents with type 2 diabetes mellitus (T2D) preferentially...
Background: It has been shown that the abrupt cessation of treatment with β-adrenoceptor antagonists...
BACKGROUND: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs-ARBs) i...
Aim. To evaluate the clinical impact of β-blocker in patients with adequate left ventricular ejectio...
Background: Long-term β-blockade therapy is beneficial in post-myocardial infarct (MI) patients with...
Aims: Guidelines concerning β-blocker treatment following acute myocardial infarction (AMI) are base...
BACKGROUND: Despite its proven efficacy, beta-blocker therapy remains underused in elderly patients ...
Objectives. —To study determinants and adverse outcomes (mortality and rehospitalization) of β-bloc...
Background Secondary prevention medications are often not prescribed to frail, older adults followin...
BackgroundEvidence regarding differences in outcomes between angiotensin II receptor blockers (ARBs)...
Background: We evaluated the burden of adverse events (AEs) caused by beta-blocker use after acute m...
ObjectivesStudies examining the effects of statins after acute myocardial infarction (AMI) excluded ...
Objectives: Studies examining the effects of statins after acute myocardial infarction (AMI) exclude...
Objectives: Studies examining the effects of statins after acute myocardial infarction (AMI) exclude...
Background/objectivesSecondary prevention medications are recommended for older adults after acute m...
AimsTo assess whether nursing home (NH) residents with type 2 diabetes mellitus (T2D) preferentially...
Background: It has been shown that the abrupt cessation of treatment with β-adrenoceptor antagonists...
BACKGROUND: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs-ARBs) i...
Aim. To evaluate the clinical impact of β-blocker in patients with adequate left ventricular ejectio...
Background: Long-term β-blockade therapy is beneficial in post-myocardial infarct (MI) patients with...
Aims: Guidelines concerning β-blocker treatment following acute myocardial infarction (AMI) are base...
BACKGROUND: Despite its proven efficacy, beta-blocker therapy remains underused in elderly patients ...